. This is a diagrammatic representation of a possible mechanism of ENL assuming an immune complex pathology. M. ieprae antigens (e) bind with antibody (y) to form localized or circulating immune complexes which are deposited in the skin,joints, kidney or endothelial cells of blood vessels. Resultant complement activation releases factors (C3a and C5a) which activate and attract phagocytes, especially PMNL and the cell membrane attack unit C5b, 6, 7, 8, 9 (00000). These cells bind to the immune complexes but are unable to ingest them (since the complexes are tissue bound). The phagocytes therefore become 'frustrated' and 'angry' with consequent degranulation and release of toxic agents such as lactoferrin, elastase, the toxic oxidizing radicals superoxide and hydroxyl radical and hydrogen peroxide which probably cause the tissue damage in ENL. The mechanisms by which these agents mediate inflammation and tissue damage have been recently reviewed.19
tolerance is mediated by recruitment of antigen-specific suppressor T -lymphocytes I which suppress specific cell-mediated immunity (CMI) to M. ieprae. Other mechanisms which decrease CMI responses to M. ieprae are also operative such as generalized anergy and humoral factors with immunosuppressive activity. Paradoxically, the induction of suppression of specific eMI is probably beneficial by reducing the degree of immunologically mediated tissue damage. However, damage to tissues is an on-going process due to non-specific and antibody mediated immune mechanisms and immunologically uncontrolled growth of M. ieprae.
The situation in individuals with LL prior to the commencement of antimicrobial chemo therapy is that they have: (a) an extremely high antigen load; and (b) specific immunological tolerance to M. ieprae.
Activation of immune reactivity in LL following antimicrobial chemotherapy
Antimicrobial agents may contribute to the development of adverse immunological reactions by either or both of two possible mechanisms:
(a) As a consequence of the antibacterial activity of the drugs with activation of latent or hitherto suppressed immunological reactions. Antimicrobial agents cause disintegration of the bacterial cells with release of antigens which form circulating or localized immune complexes. These complexes cause regional or generalized complement activation with mobilization of granulocytes which migrate to sites of immune complex deposition. Binding of granulocytes to the immune complexes with subsequent phagocytosis or exocytosis causes release of toxic oxygen radicals and proteolytic enzymes which damage surrounding tissues. It is likely that granulocyte activation by the interaction of immune complexes and complement is responsible for the development of erythema nodosum leprosum (ENL) and its complications in individuals with a high bacillary load (BL-LL).
Antigen-elimination during antimicrobial chemotherapy causes a decrease in the antigen load with a consequent reduction in the extent of antigen-induced immunosuppression and recovery of specific CMI to M. leprae. Reactivation of CMI leads to the development of an adverse immunological reaction (reversal immunity reaction) caused by the induction of production of pro-inflammatory lymphokines which mobilize, attract and activate granulocytes, macrophages and T -lymphocytes. These highly reactive cells release toxic oxidants and proteases which, although important in the intracellular destruction of microorganisms, are also released extracellularly and may mediate the tissue damage which accompanies reversal immunity reactions. These reactions may occur anywhere in the leprosy spectrum except the polar groups.
It must be emphasized that these proposed mechanisms are speculative. However, should they exist all agents used in the antimicrobial chemotherapy of leprosy have the potential to cause ENL and/or reversal immunity reactions in susceptible individuals.
(b) The second mechanism by which antimicrobial agents may contribute to the development of adverse immunological reactions is by possession of intrinsic immunostimulatory activity, i.e. direct drug-mediated enhancement of cellular immune responsiveness independent of antimicrobial activity. Such a mechanism is probably less important than antigen release mechanisms related to antimicrobial activity. However, a drug such as dapsone which has been reported to increase granulocyte motility and lymphocyte proliferation2 could be expected to potentiate ENL and reversal immunity reactions in susceptible individuals.
Effects of antileprosy drugs on cellular-immune reactivity
The three widely used antimycobacterial agents rifampicin, dapsone, and c10fazimine may regulate cellular immune fu nctions by antigen-elimination mechanisms as described above. However, in this section their effects per se on immune reactivity are considered.
RIFAMPICIN
The immunomodulating effects of rifampicin have recently been reviewed.3 This antimicrobial agent is an inhibitor of lymphocyte responses to mitogens and antigens and ofPMNL migration in vitro. Animal studies have also shown that rifampicin is immunosuppressive in vivo causing inhibition of both antibody and cell-mediated immune responses. However, studies4 have shown that rifampicin at concentrations ofO'O I-I 00 jig/ml had no effects on human monocyte migration in vitro. 4 The effects of rifampicin on humoral and cellular immunity have been investigated5 in a double blind comparison in which 33 patients with pulmonary tuberculosis were treated with streptomycin, isoniazid and rifampicin or with streptomycin, isoniazid and pyrazinamide and 41 healthy controls were treated with rifampicin or a placebo. Treatment was for 6 months with a I year fo llow-up. No effects of rifampicin could be demonstrated on parameters of humoral or cellular immunity. In two separate studies we observed no inhibitory effects of rifampicin intake on polymorphonuclear leucocyte (PMNL) migration6, 7 over a I-month period in individuals with LL and actually observed improved lymphocyte responsiveness to mitogens. The effects of rifampicin on humoral and cell-mediated immune responses appear to be variable according to the response studied and the in vivo model used. However, the presently available evidence suggests that ingestion of the antibiotic by individuals with LL and normal adults has no striking immunosup pressive effects. There is no evidence to show that rifampicin per se stimulates any cellular immune fu nction although improved lymphocyte proliferation in patients with LL may be associated with the antimicrobial activity of the antibiotic.7
DAPSONE
It has been reported from this laboratory that dapsone per se causes stimulation ofPMNL motility in normal adults and individuals with LL in vitro.2 Furthermore ingestion of the drug over short periods was associated with increased PMNL migration and lymphocyte responsiveness to mitogens in the control and LL groups , 2, 6, 7 These effects of dapsone were related to the anti-oxidant activity of the drug and not to its antimicrobial properties. Anti-oxidants sustain and enhance cellular immune reactivity by preventing the auto-oxidative loss of migratory responsive ness of PMNL and mitogen and antigen-induced lymphocyte proliferation.8 A second possible mechanism of dapsone-mediated immunostimulation, also related to an anti-oxidant mechanism, may be inhibition of the synthesis of immunosuppressive prostaglandins (PGs). Recent reports have indicated that PGs released by monocytes induce suppressor cell activity which may be the cause of the impaired eMI observed in diseases such as Hodgkin's disease.9 It has been reported'O that this PG-dependent suppression is operative in individuals with the BT and TT forms of the disease but not in the BL and LL fo rms. However, it is possible that during antimicrobial chemotherapy associated recovery of eMI in BL-LL cases that T-Iymphocytes may become more responsive to PG-mediated suppression. Inhibition by dapsone of this mechanism may therefore possibly contribute to enhanced eMI and development of reversal immunity reactions. It must be stressed, however, that there is no available data to substantiate the existence of this mechanism.
These observations suggest that dapsone is pro-inflammatory and may contribute to ENL and reversal immunity reactions by stimulating P.MNL motility and lymphocyte responsiveness to antigens respectively. However, the drug has well-documented anti-inflammatory activity in a variety of dermatological conditions" which is probably related to its ability to inhibit phagocyte degranulation.12 It has also been suggested ' 3 that dapsone may confer a measure of protection against the development of reversal immunity reactions in individuals with BL. This may seem difficult to reconcile with the proposed pro-inflammatory activity of the drug in LL. However, in individuals with LL and a high antigen load it is possible that the immunostimulatory, pro-inflammatory activities of the drug are dominant since the anti-inflammatory effect on degranulation may be negated as a result of increased leucocyte infiltration and high concentrations of immune complexes.
Clofazimine, known alternatively as lamprene (R) or B663, is also a widely used anti leprosy drug. However, c10fazimine has no documented immunostimulatory properties and on the contrary has been reported to be useful in controlling both ENLI4• IS and reversal immunity reactionslS, 16 whilst conferring antimicrobial chemotherapy. Recent investigations in this laboratory have shown that c10fazimine inhibits the motility of PMNL and mitogen-induced transformation of lymphocytes from normal adults and individuals with LL in vitro; similar effects were observed fo llowing ingestion of the drug. l 7 · 18 These observations suggest that the most probable mechanisms of c1ofazimine-mediated anti-inflammatory activity are inhibition of PMNL migration and T lymphocyte responsiveness to antigens which may control ENL and reversal immunity reactions respectively. Although the drug is therapeutically useful as a combined anti-inflammatory and antimicrobial agent its ability to precipitate adverse immunological reactions in susceptible individuals by antigen release mechanisms should, however, not be underestimated.
Conclusions
Inadvertent immunological manipulation occurs during antimicrobial therapy of individuals with leprosy with possible development of adverse immunological reactions in some cases , This is due to the formation of immune complexes and loss of antigen-induced immunosuppression and occurs as a consequence of the antimicrobial activity of the drugs. Rifampicin, dapsone and c10fazimine may precipitate ENL arid reveral immunity reactions by this mechanism. Dapsone-associated reactions may be intensified by the ability of the drug per se to potentiate PMNL migration and T -lymphocyte proliferation. Clofazimine, however, is immunosuppressive and may be useful in the control and prevention of such reactions whilst continuing to provide antimicrobial chemotherapy.
